January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Bruce Feinberg, DO; Kathy Oubre, Michael Reff, RPh, MBA; Jamile M. Shammo, MD; and Ruben Mesa, MD, discuss the incorporation of quality care programs for improved disease management and patient care for MPNs.
Report of Second Texas Nurse With Ebola Fans Hospital Safety Fears
In Texas Ebola Case, Was Patient's Insurance Status an Issue?
WHO: Ebola Outbreak Is International Public Health Emergency